Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Prostate Cancer

Free Subscription Articles published in Int J Radiat Oncol Biol Phys Retrieve available abstracts of 127 articles: HTML format

Single Articles

May 2026
1. SHERRY AD, Ludmir EB, Tang C
   Setting the TRAP for Oligoprogressive Prostate Cancer: The Impetus for Prospective Evidence.
   Int J Radiat Oncol Biol Phys. 2026;125:295-297.
   PubMed    
   
   
   
2. ZILLI T, Zaorsky NG, Maitre P, Desai N, et al
   Metastasis-directed Therapy in Oligometastatic Castration-resistant Prostate Cancer: From Chasing the Last Metastasis to Changing the Game?
   Int J Radiat Oncol Biol Phys. 2026;125:11-14.
   PubMed    
   
   
   
3. SINGH M, Katdare A, Ghosh S, Choudhury S, et al
   PSMA-PET-Guided Intraprostatic Boost in Prostate SBRT (PROBE): A Phase 2 Trial.
   Int J Radiat Oncol Biol Phys. 2026;125:203-213.
   PubMed     Abstract available
   
   
   
4. RATNAKUMARAN R, Sasitharan A, Khan A, Mayet H, et al
   Dosimetric Comparison of CyberKnife and Conventional Linac Prostate Stereotactic Body Radiation Therapy Plans: Analysis of the PACE-B Study.
   Int J Radiat Oncol Biol Phys. 2026;125:250-256.
   PubMed     Abstract available
   
   
   April 2026
5. MULVANEY O, Chung JS, Kobayashi M, Somatilaka BG, et al
   GPNMB(+) MDSCs Mediate Radiation-Induced Immune Suppression in Prostate Cancer and Are Targetable to Improve Systemic Control.
   Int J Radiat Oncol Biol Phys. 2026 Apr 30:S0360-3016(26)00656.
   PubMed     Abstract available
   
   
   
6. HOWARD TP, Walburn T, Benham G, Chirmade S, et al
   Four-Year Feasibility and Safety Results of a Phase 1/2 Single-Arm Prospective Clinical Trial of Stereotactic Magnetic Resonance-Guided Adaptive Radiation Therapy for Metachronous Oligometastatic Abdominopelvic Lymph Node and Soft Tissue Metastases.
   Int J Radiat Oncol Biol Phys. 2026;124:1404-1410.
   PubMed     Abstract available
   
   
   March 2026
7. ANGER E, Supiot S, Josset Q, Pasquier D, et al
   Pushing the boundaries of SBRT in irradiated territories for nodal oligorecurrent prostate cancer: outcomes of the CYGNUS multicentric retrospective study.
   Int J Radiat Oncol Biol Phys. 2026 Mar 19:S0360-3016(26)00502.
   PubMed     Abstract available
   
   
   
8. HOWELL JN, Wilkes J, Maughan NM, Patel RB, et al
   Industry Sponsorship and Disease Site Focus in Therapeutic Radiopharmaceutical Clinical Trials Over the Past Decade.
   Int J Radiat Oncol Biol Phys. 2026;124:575-580.
   PubMed     Abstract available
   
   
   February 2026
9. VARGAS CE, Voss MM, Dodoo C, Wong W, et al
   Outcomes of a Phase II Interventional Clinical Trial of Prostate Bed Stereotactic Body Radiation Therapy for Prostate Cancer with High-Risk Features Following Radical Prostatectomy.
   Int J Radiat Oncol Biol Phys. 2026 Feb 17:S0360-3016(26)00328.
   PubMed     Abstract available
   
   
   
10. SHEN J, Chen RC, Sayan M, Shen X, et al
    Changes over time in total Medicare costs for active surveillance versus radiotherapy in prostate cancer.
    Int J Radiat Oncol Biol Phys. 2026 Feb 14:S0360-3016(26)00387.
    PubMed     Abstract available
    
    
    January 2026
11. KEALL PJ, Booth J, Eade T, Hewson EA, et al
    The KIM real-time prostate cancer IGRT technology journey: From clinical trials to your clinic.
    Int J Radiat Oncol Biol Phys. 2026 Jan 18:S0360-3016(26)00083.
    PubMed     Abstract available
    
    
    
12. VAN VLIET C, Tetar SU, Bohoudi O, Cobussen P, et al
    Long-term outcomes of Stereotactic MRI-guided adaptive radiotherapy (SMART) for prostate cancer: Results from a real world large patient cohort.
    Int J Radiat Oncol Biol Phys. 2026 Jan 14:S0360-3016(26)00065.
    PubMed     Abstract available
    
    
    
13. YASAR B, Suh YE, Chapman E, Nicholls L, et al
    2-year outcomes of the SPARC phase II trial: Simultaneous focal boost with stereotactic radiotherapy for localised intermediate to high-risk prostate cancer.
    Int J Radiat Oncol Biol Phys. 2026 Jan 11:S0360-3016(26)00019.
    PubMed     Abstract available
    
    
    
14. PERRIN J, Overdevest N, Tamborino G, Nonnekens J, et al
    Evaluating the Immune Response After Targeted Radionuclide Therapy: Toward a Correlation Between Absorbed Dose and Response.
    Int J Radiat Oncol Biol Phys. 2026;124:177-189.
    PubMed     Abstract available
    
    
    November 2025
15. YASAR B, Chapman E, Taylor H, Parker C, et al
    Predictors of long-term disease-free survival with stereotactic body radiotherapy for metachronous oligometastatic prostate cancer.
    Int J Radiat Oncol Biol Phys. 2025 Nov 29:S0360-3016(25)06527.
    PubMed     Abstract available
    
    
    
16. FERREIRA CA, Potluri HK, Tantawy AA, Massey C, et al
    Enhanced Antitumor Efficacy of (225)Ac-NM600 Compared to (177)Lu-NM600 in Murine Prostate Cancer Models.
    Int J Radiat Oncol Biol Phys. 2025 Nov 28:S0360-3016(25)06341.
    PubMed     Abstract available
    
    
    
17. DASSEN MG, Tree AC, Wiersema L, Neijndorff B, et al
    Primary endpoint analysis of the phase II DESTINATION-MRL trial for patients with intermediate-risk prostate cancer.
    Int J Radiat Oncol Biol Phys. 2025 Nov 26:S0360-3016(25)06502.
    PubMed     Abstract available
    
    
    
18. NABID A, Carrier N, Vigneault E, Martin AG, et al
    Impact of Persistent Hypogonadism on Overall Survival After Androgen Deprivation Therapy in Localized Prostate Cancer Patients: Long-Term Prospective Data.
    Int J Radiat Oncol Biol Phys. 2025 Nov 23:S0360-3016(25)06335.
    PubMed     Abstract available
    
    
    
19. SAYAN M, Miric G, Wallner KE, King MT, et al
    Beyond the Beam: Redefining Survivorship in Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2025;123:1000-1003.
    PubMed    
    
    
    
20. LUKKA HR, Pugh SL, Shipley WU, Major PP, et al
    Long-Term Results of NRG/RTOG 9601, a Randomized Trial of Radiation With or Without Antiandrogens in Patients Receiving Salvage Prostate Bed Radiation Therapy Postprostatectomy.
    Int J Radiat Oncol Biol Phys. 2025;123:990-999.
    PubMed     Abstract available
    
    
    
21. DONG A, Sun X, Chen L, Tsai Y, et al
    KDM3B Regulates Postradiation Fibrotic Responses in Prostate Stroma via N(6)-methyladenosine Modification of LOX.
    Int J Radiat Oncol Biol Phys. 2025;123:1116-1131.
    PubMed     Abstract available
    
    
    
22. FITZPATRICK KJ, Mikell JK, Roseland ME, Niedbala J, et al
    (177)Lu-PSMA-617 Single-Photon Emission Computed Tomography/Computed Tomography Dosimetry and Radiobiological Models Demonstrate Decreasing Tumor-to-Kidney Dose Ratio With Successive Cycles.
    Int J Radiat Oncol Biol Phys. 2025;123:937-946.
    PubMed     Abstract available
    
    
    
23. COOPER S, Westley RL, Biscombe K, Dunlop A, et al
    HERMES: Randomized Trial of 2-Fraction or 5-Fraction Magnetic Resonance Imaging-Guided Adaptive Prostate Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2025;123:773-782.
    PubMed     Abstract available
    
    
    
24. YAZDANI E, Sadeghi M, Karamzade-Ziarati N, Jabari P, et al
    Machine Learning-based Dose Prediction in [(177)Lu]Lu-PSMA-617 Therapy by Integrating Biomarkers and Radiomic Features from [(68)Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography.
    Int J Radiat Oncol Biol Phys. 2025;123:891-908.
    PubMed     Abstract available
    
    
    October 2025
25. JONGEN CA, Heijmen BJ, Incrocci L, Heemsbergen WD, et al
    Radiobiological Modeling for Acute Proctitis after Conventional and Hypofractionated Radiotherapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2025 Oct 23:S0360-3016(25)06385.
    PubMed     Abstract available
    
    
    
26. ZACHARAKI EI, Breto AL, Algohary A, Wallaengen V, et al
    Integration of Habitat Risk Score (HRS) in Radiotherapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2025 Oct 23:S0360-3016(25)06347.
    PubMed     Abstract available
    
    
    
27. WIERSMA RG, de Vries KC, Heemsbergen WD, de Hoop EO, et al
    Hypofractionated Dose Escalation versus Conventionally Fractionated Radiotherapy for Patients with Intermediate- and High-risk Localized Prostate Cancer: Long-term Results of the HYPRO trial.
    Int J Radiat Oncol Biol Phys. 2025 Oct 15:S0360-3016(25)06340.
    PubMed     Abstract available
    
    
    
28. SAAD E, Hoskin P, Choudhury A
    Prophylactic Pelvic Nodal Radiation Therapy in High-risk Node-negative Prostate Cancer: The Case Against.
    Int J Radiat Oncol Biol Phys. 2025;123:392-394.
    PubMed    
    
    
    
29. TISSEVERASINGHE S, Niazi T
    Pelvic Nodal Irradiation Should Be Offered to High-Risk Prostate Cancer Patients Receiving Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2025;123:387-391.
    PubMed    
    
    
    
30. ACHARD V, Benziane-Ouaritini N, Sargos P
    Hypofractionated Radiation Therapy for Prostate Cancer in the Postoperative Setting: Is It Capable of Going the Distance?
    Int J Radiat Oncol Biol Phys. 2025;123:381-383.
    PubMed    
    
    
    
31. RAMADAN S, Loblaw A, Dhar A, Fakir H, et al
    PSMA MRI Guided prOstate SBRT (ARGOS)/Comprehensive, Longitudinal Evaluation of IMaging BiomarkErs Post Radiotherapy (CLIMBER) Phase I/II Trial.
    Int J Radiat Oncol Biol Phys. 2025;123:395-405.
    PubMed     Abstract available
    
    
    
32. RANTA K, Wojcieszynski AP, Zhao SG, Liu Y, et al
    Severe Late Toxicities (Grade 3-5) With 13 Years of Follow-up after Hypofractionated Postprostatectomy Radiotherapy.
    Int J Radiat Oncol Biol Phys. 2025;123:374-380.
    PubMed     Abstract available
    
    
    September 2025
33. NEILSEN BK, Huang RR, Valle LF, Proudfoot JA, et al
    Genomic and Transcriptomic Profiling of Radiation-Resistant, Locally Recurrent Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2025 Sep 29:S0360-3016(25)06298.
    PubMed     Abstract available
    
    
    
34. YU JB, DeStephano DM, Jeffers B, Tward AE, et al
    The Comparative Toxicity of Focal Ablation vs. IMRT for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2025 Sep 23:S0360-3016(25)06282.
    PubMed     Abstract available
    
    
    
35. LUDDY KA, West J, Robertson-Tessi M, Desai B, et al
    Evolutionary double-bind treatment using radiotherapy and NK cell-based immunotherapy in prostate cancer.
    Int J Radiat Oncol Biol Phys. 2025 Sep 23:S0360-3016(25)06293.
    PubMed     Abstract available
    
    
    
36. SONG Y, Dornisch AM, Dess RT, Margolis DJA, et al
    Multidisciplinary Consensus Prostate Contours on Magnetic Resonance Imaging: Educational Atlas and Reference Standard for Artificial Intelligence Benchmarking.
    Int J Radiat Oncol Biol Phys. 2025;123:183-194.
    PubMed     Abstract available
    
    
    August 2025
37. ONG WL, Davidson M, Wronski M, Kang T, et al
    Bowel bag dosimetric parameters for ultrahypofractionated pelvic elective nodal irradiation in prostate cancer.
    Int J Radiat Oncol Biol Phys. 2025 Aug 15:S0360-3016(25)06145.
    PubMed     Abstract available
    
    
    July 2025
38. HAMSTRA DA, Dignam JJ, Bruner DW, Michaelson MD, et al
    Phase III trial of dose escalated radiation therapy and standard androgen deprivation therapy (ADT) vs. dose escalated radiation therapy and enhanced ADT with orteronel for men with high-risk prostate cancer (NRG/RTOG 1115).
    Int J Radiat Oncol Biol Phys. 2025 Jul 23:S0360-3016(25)06022.
    PubMed     Abstract available
    
    
    
39. ONAL C, Guler OC, Torun N, Demirhan B, et al
    Gallium-68-Labeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Response in Pelvic Node-Positive Prostate Cancer After Definitive Radiation Therapy: Prognostic Implications.
    Int J Radiat Oncol Biol Phys. 2025 Jul 17:S0360-3016(25)04496.
    PubMed     Abstract available
    
    
    
40. PATEL RK, Lee J, Patel M, Zaorsky NG, et al
    Evolution of Image Guidance and Adaptive Radiation Therapy for Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2025;122:968-975.
    PubMed     Abstract available
    
    
    
41. KEALL PJ, El Naqa I, Fast MF, Hewson EA, et al
    Real-Time Dose-Guided Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2025;122:787-801.
    PubMed     Abstract available
    
    
    
42. SNYDER JE, Fast MF, Uijtewaal P, Borman PTS, et al
    Enhancing Delivery Efficiency on the Magnetic Resonance-Linac: A Comprehensive Evaluation of Prostate Stereotactic Body Radiation Therapy Using Volumetric Modulated Arc Therapy.
    Int J Radiat Oncol Biol Phys. 2025;122:976-985.
    PubMed     Abstract available
    
    
    
43. PATEL KR, Mena E, Rowe LS, Ning H, et al
    A Phase 1 Trial of Image Guided Risk Volume-Adapted Postprostatectomy Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2025;122:986-994.
    PubMed     Abstract available
    
    
    
44. HOWARD TP, Ferguson D, Han Z, Mamon HJ, et al
    Magnetic Resonance-Guided Stereotactic Body Radiation Therapy With Daily Online Plan Adaptation for Reirradiation in the Abdomen.
    Int J Radiat Oncol Biol Phys. 2025;122:752-759.
    PubMed     Abstract available
    
    
    
45. VAN WERKHOVEN LA, Milder MTW, Hoogeman MS, van Werkhoven E, et al
    Results of a Single-Arm Phase 2 Clinical Trial: Online Adaptive Stereotactic Body Radiation Therapy for Abdominal-Pelvic Oligometastases.
    Int J Radiat Oncol Biol Phys. 2025;122:729-738.
    PubMed     Abstract available
    
    
    June 2025
46. COURTNEY PT, Dong H, Lao Y, Pham J, et al
    Dosimetric Comparison of MRI-Guided Versus Reduced Margin CT-Guided Stereotactic Body Radiotherapy for Localized Prostate Cancer: Post-Hoc Analysis of a Phase III Trial.
    Int J Radiat Oncol Biol Phys. 2025 Jun 5:S0360-3016(25)00553.
    PubMed     Abstract available
    
    
    
47. DICKSTEIN DR, Kapouranis T, Sigel K, Wheldon CW, et al
    Sexual Health Outcomes in Sexual Minority and Heterosexual Men After Prostate Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2025;122:416-423.
    PubMed     Abstract available
    
    
    May 2025
48. GOULET M, Duguay-Drouin P, Mascolo-Fortin J, Megroureche J, et al
    Clinical Application of Deep Learning-Assisted Needles Reconstruction in Prostate Ultrasound Brachytherapy.
    Int J Radiat Oncol Biol Phys. 2025;122:199-207.
    PubMed     Abstract available
    
    
    April 2025
49. CROOK J, Cheng JC, Arbour G, Araujo C, et al
    A Randomized Comparison of High Dose Rate and Low Dose Rate Prostate Brachytherapy Combined with External Beam Radiotherapy for Unfavourable Prostate Cancer: Efficacy Results after Median Follow-up 74 Months.
    Int J Radiat Oncol Biol Phys. 2025 Apr 3:S0360-3016(25)00303.
    PubMed     Abstract available
    
    
    
50. MAITRE P, Zaorsky NG, Dess RT, Koontz BF, et al
    Precision Over Tradition: Transforming Prostate Cancer Treatment with Stereotactic Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2025;121:1093-1097.
    PubMed    
    
    
    
51. CHEN J, Yang Y, Feng H, Zhang L, et al
    Robust Optimization for Spot-Scanning Proton Therapy based on Dose-Linear-Energy-Transfer Volume Constraints.
    Int J Radiat Oncol Biol Phys. 2025;121:1303-1315.
    PubMed     Abstract available
    
    
    March 2025
52. PATEL P, Dreibe S, Attard G, Cole A, et al
    Stereotactic body radiotherapy for oligoprogressive disease in androgen suppressed prostate cancer: Primary endpoint analysis of the TRAP trial.
    Int J Radiat Oncol Biol Phys. 2025 Mar 9:S0360-3016(25)00225.
    PubMed     Abstract available
    
    
    
53. VENKATESULU BP, Adams W, Joel R, Ross D, et al
    The Importance of Multi-parametric MRI, PET/CT, and Biopsy for Identifying and Delineating the Extent of Intraprostatic Radiorecurrent Prostate Cancer: A Secondary Analysis of the F-SHARP Clinical Trial.
    Int J Radiat Oncol Biol Phys. 2025 Mar 6:S0360-3016(25)00193.
    PubMed     Abstract available
    
    
    
54. MONINGI S, Orio PF 3rd
    An Aggressive Approach for Mucinous Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2025;121:584.
    PubMed    
    
    
    
55. REARDON MD, Bibby BAS, Thiruthaneeswaran N, Pereira RR, et al
    Hypoxia-Associated Gene Signatures Are Not Prognostic in High-Risk Localized Prostate Cancers Undergoing Androgen Deprivation Therapy With Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2025;121:752-760.
    PubMed     Abstract available
    
    
    
56. BROOKS FMD, Glenn MC, Hernandez V, Saez J, et al
    Is the Imaging Radiation Oncology Core Head and Neck Credentialing Phantom an Effective Surrogate for Different Anatomic Sites?
    Int J Radiat Oncol Biol Phys. 2025;121:811-821.
    PubMed     Abstract available
    
    
    
57. FENG H, Shan J, Vargas CE, Keole SR, et al
    Online Adaptive Proton Therapy Facilitated by Artificial Intelligence-Based Autosegmentation in Pencil Beam Scanning Proton Therapy.
    Int J Radiat Oncol Biol Phys. 2025;121:822-831.
    PubMed     Abstract available
    
    
    
58. LE REUN E, Espenel S, Garcia MA, Girbovan AH, et al
    Image-Guided Brachytherapy for Pediatric Bladder and/or Prostate Rhabdomyosarcoma: Toward an Increased Personalization of Treatment.
    Int J Radiat Oncol Biol Phys. 2025;121:658-666.
    PubMed     Abstract available
    
    
    February 2025
59. TWARD J, Lloyd S, Johnson S, Dechet C, et al
    A Phase 2 Trial of Radium(223) and Stereotactic Ablative Radiotherapy in Hormone-Naive Men with Oligometastatic Prostate Cancer to Bone: The RadSABR study.
    Int J Radiat Oncol Biol Phys. 2025 Feb 6:S0360-3016(25)00095.
    PubMed     Abstract available
    
    
    
60. PATEL KR, Spratt DE, Tran PT, Krauss DJ, et al
    The Benefit of Short-Term Androgen Deprivation Therapy with Radiotherapy for Intermediate-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2025 Feb 6:S0360-3016(25)00086.
    PubMed     Abstract available
    
    
    
61. LANGE M, Campion L, Ollivier L, Renouf M, et al
    Patterns of relapse following radiotherapy of intermediate-risk (IR) prostate cancer (PCa) on the PROFIT randomized trial.
    Int J Radiat Oncol Biol Phys. 2025 Feb 4:S0360-3016(25)00089.
    PubMed     Abstract available
    
    
    
62. ZAMBOGLOU C, Arcangeli S, Kamran SC
    Stereotactic Body Radiation Therapy for Prostate Cancer is Getting Mature: 10-Year Outcomes From 3 Prospective Trials.
    Int J Radiat Oncol Biol Phys. 2025;121:331-332.
    PubMed    
    
    
    January 2025
63. PATEL KR, Pra AD, Huang EP, Singh SA, et al
    The Determinants of Toxicity in the Treatment of Prostate Cancer with a Focal, Intraprostatic "Microboost".
    Int J Radiat Oncol Biol Phys. 2025 Jan 22:S0360-3016(25)00054.
    PubMed     Abstract available
    
    
    
64. MURTHY V, Mallick I, Maitre P, Mulye G, et al
    Pelvic regional control with 25Gy in 5 fractions in SBRT for high risk prostate cancer: Pooled prospective outcomes from the SHARP consortium.
    Int J Radiat Oncol Biol Phys. 2025 Jan 2:S0360-3016(24)03773.
    PubMed     Abstract available
    
    
    
65. ZHANG P, Happersett L, Burleson S, Oh JH, et al
    Reduction of Postradiation Therapy Urinary Toxicity Via Intrafractional Megavoltage-Kilovoltage Prostate Location Monitoring.
    Int J Radiat Oncol Biol Phys. 2025;121:261-268.
    PubMed     Abstract available
    
    
    
66. RAJENDRAN P, Chen Y, Qiu L, Niedermayr T, et al
    Autodelineation of Treatment Target Volume for Radiation Therapy Using Large Language Model-Aided Multimodal Learning.
    Int J Radiat Oncol Biol Phys. 2025;121:230-240.
    PubMed     Abstract available
    
    
    December 2024
67. CHOO R, Corbin K, Merrell K, Stish B, et al
    Five-year outcomes of moderately hypofractionated proton therapy incorporating elective pelvic nodal irradiation for high-risk prostate cancer.
    Int J Radiat Oncol Biol Phys. 2024 Dec 11:S0360-3016(24)03722.
    PubMed     Abstract available
    
    
    
68. SONG D, Dabkowski M, Costa P, Nurani R, et al
    Prospective, Randomized Controlled Pivotal Trial of Biodegradable Balloon Rectal Spacer for Prostate Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2024;120:1410-1420.
    PubMed     Abstract available
    
    
    
69. ARCANGELI S, Chissotti C, Ferrario F, Lucchini R, et al
    Ablative Radiation Therapy for Unfavorable Prostate Tumors (ABRUPT): Preliminary Analysis of Toxicity and Quality of Life from a Prospective Study.
    Int J Radiat Oncol Biol Phys. 2024;120:1394-1403.
    PubMed     Abstract available
    
    
    November 2024
70. FRANCOLINI G, Di Cataldo V, Garlatti P, Simontacchi G, et al
    Androgen Deprivation Therapy in Intermediate Prostate Cancer Treated With Radiation Therapy: The Wide Heterogeneity and Complexity of an Apparently Simple Situation.
    Int J Radiat Oncol Biol Phys. 2024;120:1008-1010.
    PubMed    
    
    
    
71. SINGH M, Maitre P, Krishnan A, Adsul K, et al
    Late Urinary Toxicity After Extreme or Moderate Hypofractionated Prostate Radiation Therapy in Patients With Prior Transurethral Resection of Prostate.
    Int J Radiat Oncol Biol Phys. 2024;120:1011-1020.
    PubMed     Abstract available
    
    
    
72. FUKUOKAYA W, Miki K, Aoki M, Takahashi H, et al
    Ten-year outcomes of a phase III, multicenter, randomized controlled trial (SHIP0804) with three-month neoadjuvant androgen deprivation prior to (125)I-seed transperineal prostate brachytherapy followed by nil versus nine-month adjuvant hormonal thera
    Int J Radiat Oncol Biol Phys. 2024 Nov 15:S0360-3016(24)03584.
    PubMed     Abstract available
    
    
    
73. OST P, Mottet N
    PSMA PET-CT, When Seeing Becomes Improving.
    Int J Radiat Oncol Biol Phys. 2024;120:646-647.
    PubMed    
    
    
    
74. MURPHY DG, Emmett L
    PSMA PET Staging is Advised for All High-Risk Patients With Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2024;120:642-645.
    PubMed    
    
    
    
75. MANNAR D, Liu W
    When Seeds Fail: Local Recurrence of Prostate Cancer Within a Seminal Vesicle After Brachytherapy.
    Int J Radiat Oncol Biol Phys. 2024;120:621-623.
    PubMed    
    
    
    September 2024
76. WISDOM AJ, Yeap BY, Michalski JM, Horick NK, et al
    Setting the Stage: Feasibility and Baseline Characteristics in the PARTIQoL Trial Comparing Proton Therapy vs. IMRT for Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2024 Sep 26:S0360-3016(24)03444.
    PubMed     Abstract available
    
    
    
77. MORGAN KM, Deshler LN, Tibbs MD, Qiao EM, et al
    Prostate Specific Antigen and Prostate Cancer in Gender Affirming Hormone Therapy for Transgender or Nonbinary Individuals.
    Int J Radiat Oncol Biol Phys. 2024 Sep 25:S0360-3016(24)03409.
    PubMed     Abstract available
    
    
    
78. KENNEDY TAC, Ong WL, Quon H, Cheung P, et al
    Stereotactic radiotherapy for localized prostate cancer: 10-year outcomes from three prospective trials.
    Int J Radiat Oncol Biol Phys. 2024 Sep 16:S0360-3016(24)03368.
    PubMed     Abstract available
    
    
    
79. UDOVICICH C, Jia AY, Loblaw A, Eapen R, et al
    Evolving Paradigms in Prostate Cancer: The Integral Role of PSMA PET/CT in Primary Staging and Therapeutic Decision-Making.
    Int J Radiat Oncol Biol Phys. 2024 Sep 13:S0360-3016(24)03387.
    PubMed     Abstract available
    
    
    
80. DESAI NB, Nagar H
    Point: Rectal Spacer Use is Recommended for All Prostate Cancer Radiation Therapy Fractionation Regimens.
    Int J Radiat Oncol Biol Phys. 2024;120:33-35.
    PubMed    
    
    
    
81. CROOK J, Moideen N, Arbour G, Castro F, et al
    A Randomized Trial Comparing Quality of Life After Low-Dose Rate or High-Dose Rate Prostate Brachytherapy Boost With Pelvic External Beam Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2024;120:59-68.
    PubMed     Abstract available
    
    
    August 2024
82. ODEN J, Eriksson K, Pavoni B, Crezee H, et al
    A Novel Framework for Thermoradiotherapy Treatment Planning.
    Int J Radiat Oncol Biol Phys. 2024;119:1530-1544.
    PubMed     Abstract available
    
    
    July 2024
83. ROY S, MacRae R, Grimes S, Malone J, et al
    Helical Tomotherapy versus Three-Dimensional Conformal Radiotherapy in High Risk Prostate Cancer: A Phase III Randomized Controlled Trial.
    Int J Radiat Oncol Biol Phys. 2024 Jul 13:S0360-3016(24)02957.
    PubMed     Abstract available
    
    
    
84. FREDMAN E, Moore A, Icht O, Tschernichovsky R, et al
    Acute toxicity and early PSA response after two-fraction stereotactic radiotherapy for localized prostate cancer using peri-rectal spacing - Initial report of the SABR-Dual trial.
    Int J Radiat Oncol Biol Phys. 2024 Jul 11:S0360-3016(24)02947.
    PubMed     Abstract available
    
    
    
85. TOESCA DAS, Hartsell WF, DeWees TA, Chang JH, et al
    Stereotactic Body Proton Therapy Versus Conventionally Fractionated Proton Therapy for Early Prostate Cancer: A Randomized, Controlled, Phase 3 Trial.
    Int J Radiat Oncol Biol Phys. 2024 Jul 5:S0360-3016(24)00669.
    PubMed     Abstract available
    
    
    
86. NIKITAS J, Ong WL, Carrier N, Romero T, et al
    Prostate-Specific Antigen Response to Androgen Deprivation Therapy in the Neoadjuvant Setting for High-Risk Prostate Adenocarcinoma (PIRANHA): Pooled Analysis of Two Randomized Clinical Trials.
    Int J Radiat Oncol Biol Phys. 2024;119:826-831.
    PubMed     Abstract available
    
    
    
87. ONG WL, Nikitas J, Joseph D, Steigler A, et al
    Long-Term Quality-of-Life Outcomes After Prostate Radiation Therapy With or Without High-Dose-Rate Brachytherapy Boost: Post Hoc Analysis of TROG 03.04 RADAR.
    Int J Radiat Oncol Biol Phys. 2024;119:813-825.
    PubMed     Abstract available
    
    
    June 2024
88. ZHONG AY, Lui AJ, Kuznetsova S, Kallis K, et al
    Clinical Impact of Contouring Variability for Prostate Cancer Tumor Boost.
    Int J Radiat Oncol Biol Phys. 2024 Jun 24:S0360-3016(24)00740.
    PubMed     Abstract available
    
    
    
89. DYKSTRA M, Regan S, Yin H, McLaughlin P, et al
    Variation in Androgen Deprivation Therapy Use Among Men with Intermediate Risk Prostate Cancer: Results from a Statewide Radiation Oncology Quality Consortium.
    Int J Radiat Oncol Biol Phys. 2024 Jun 4:S0360-3016(24)00689.
    PubMed     Abstract available
    
    
    
90. WESTERHOFF JM, Lalmahomed TA, Meijers L, Henke L, et al
    Patient reported outcomes following MR-guided radiotherapy for prostate cancer: a systematic review and meta-analysis.
    Int J Radiat Oncol Biol Phys. 2024 Jun 3:S0360-3016(24)00691.
    PubMed     Abstract available
    
    
    May 2024
91. ALEXANDER GS, Krc RF, Assif JW, Sun K, et al
    Conditional Risk and Predictive Factors Associated with Late Toxicity for Prostate Cancer Patients Treated with External Beam Radiotherapy Alone on Randomized Trial RTOG 0126.
    Int J Radiat Oncol Biol Phys. 2024 May 31:S0360-3016(24)00686.
    PubMed     Abstract available
    
    
    
92. GLOWA C, Bendinger AL, Euler-Lange R, Peschke P, et al
    Irradiation with carbon ions effectively counteracts hypoxia-related radioresistance in a rat prostate carcinoma.
    Int J Radiat Oncol Biol Phys. 2024 May 13:S0360-3016(24)00627.
    PubMed     Abstract available
    
    
    
93. ALEXANDER A, Gagne I, Bahl G, Kim D, et al
    Late Toxicity of Prostate Ultrahypofractionated Radiation Therapy Compared With Moderate Hypofractionation in a Randomized Trial.
    Int J Radiat Oncol Biol Phys. 2024;119:110-118.
    PubMed     Abstract available
    
    
    
94. SUN Y, Tsai Y, Wood R, Shen B, et al
    KDM3B Single-Nucleotide Polymorphisms Impact Radiation Therapy Toxicity Through Circular RNA-Mediated KDM3B Expression and Inflammatory Responses.
    Int J Radiat Oncol Biol Phys. 2024;119:251-260.
    PubMed     Abstract available
    
    
    
95. ROY S, Malone S, Sun Y, Zaorsky NG, et al
    Effect of Pelvic External Beam Radiation Therapy on Bone Mineral Density: A Secondary Analysis of a Phase 3 Randomized Controlled Trial.
    Int J Radiat Oncol Biol Phys. 2024;119:119-126.
    PubMed     Abstract available
    
    
    April 2024
96. BAKER S, Lechner L, Liu M, Chang JS, et al
    Upfront Versus Delayed Systemic Therapy in Patients With Oligometastatic Cancer Treated With SABR in the Phase 2 SABR-5 Trial.
    Int J Radiat Oncol Biol Phys. 2024;118:1497-1506.
    PubMed     Abstract available
    
    
    
97. MERCIER C, Billiet C, Ost P, Joye I, et al
    Long-Term Results of a Phase 1 Dose Escalation Trial of Ablative Stereotactic Body Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2024;118:1490-1496.
    PubMed     Abstract available
    
    
    
98. LEE K, Lall R, Chopra S, Evans MJ, et al
    SENTRI: Single-Particle Energy Transducer for Radionuclide Injections for Personalized Targeted Radionuclide Cancer Therapy.
    Int J Radiat Oncol Biol Phys. 2024;118:1575-1584.
    PubMed     Abstract available
    
    
    March 2024
99. MAITRE P, Maheshwari G, Sarkar J, Singh P, et al
    Late urinary toxicity and QOL with pelvic radiotherapy for high-risk prostate cancer: Dose-effect relations in the POP-RT randomized phase III trial.
    Int J Radiat Oncol Biol Phys. 2024 Mar 27:S0360-3016(24)00439.
    PubMed     Abstract available
    
    
    
100. YASAR B, Suh YE, Chapman E, Nicholls L, et al
     Simultaneous focal boost with stereotactic radiotherapy for localised intermediate to high-risk prostate cancer: Primary outcomes of the SPARC phase II trial.
     Int J Radiat Oncol Biol Phys. 2024 Mar 16:S0360-3016(24)00425.
     PubMed     Abstract available
     
     
     
101. NEILSEN BK, Ma TM, Akingbemi WO, Neylon J, et al
     Impact of Interfractional Bladder and Trigone Displacement and Deformation on Radiation Exposure and Subsequent Acute Genitourinary Toxicity: A Post Hoc Analysis of Patients Treated with Magnetic Resonance Imaging-Guided Prostate Stereotactic Body Rad
     Int J Radiat Oncol Biol Phys. 2024;118:986-997.
     PubMed     Abstract available
     
     
     
102. WESTLEY RL, Biscombe K, Dunlop A, Mitchell A, et al
     Interim Toxicity Analysis From the Randomized HERMES Trial of 2- and 5-Fraction Magnetic Resonance Imaging-Guided Adaptive Prostate Radiation Therapy.
     Int J Radiat Oncol Biol Phys. 2024;118:682-687.
     PubMed     Abstract available
     
     
     
103. STAAL FHE, Janssen J, Oprea-Lager DE, Engelen AM, et al
     Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Based Clinical Target Volume Delineation Guideline for Postprostatectomy Salvage Radiation Therapy: The PERYTON Guideline.
     Int J Radiat Oncol Biol Phys. 2024;118:688-696.
     PubMed     Abstract available
     
     
     February 2024
104. PATEL KR, Rydzewski NR, Schott E, Cooley-Zgela T, et al
     A Phase I Trial of Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer After Brachytherapy.
     Int J Radiat Oncol Biol Phys. 2024 Feb 28:S0360-3016(24)00323.
     PubMed     Abstract available
     
     
     
105. BESUGLOW J, Tessonnier T, Mein S, Eichkorn T, et al
     Understanding RBE and clinical outcome of prostate cancer therapy using particle irradiation: analysis of tumor control probability with mMKM.
     Int J Radiat Oncol Biol Phys. 2024 Feb 27:S0360-3016(24)00331.
     PubMed     Abstract available
     
     
     
106. KING MT, Orio PF, D'Amico AV
     Can Extreme Dose Escalation With External Beam Radiation Therapy and Low-Dose-Rate Brachytherapy Boost Obviate the Need for Long-Term Androgen Deprivation Therapy in Patients With High-Risk Localized Prostate Cancer?
     Int J Radiat Oncol Biol Phys. 2024;118:402-403.
     PubMed    
     
     
     January 2024
107. TAM A, Li YR
     Ignorance is Bliss? A Case of Incidental Discovery of ATM Mutation in Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2024;118:8-9.
     PubMed    
     
     
     
108. MORGAN SC, Hu C, Dess RT
     A New Pos-SIB-ility for Prostate and Pelvic Nodal Radiation Therapy in High-Risk Localized Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2024;118:63-65.
     PubMed    
     
     
     
109. TSUI JMG, Kehayias CE, Leeman JE, Nguyen PL, et al
     Assessing the Feasibility of Using Artificial Intelligence-Segmented Dominant Intraprostatic Lesion for Focal Intraprostatic Boost With External Beam Radiation Therapy.
     Int J Radiat Oncol Biol Phys. 2024;118:74-84.
     PubMed     Abstract available
     
     
     December 2023
110. CHOUDHURY M, Thomas SS, Cain A, Palvai S, et al
     Timing of High-Dose Rate Brachytherapy with External Beam Radiotherapy in intermediate and high-risk localised Prostate Cancer (THEPCA): a randomised trial.
     Int J Radiat Oncol Biol Phys. 2023 Dec 30:S0360-3016(23)08137.
     PubMed     Abstract available
     
     
     
111. NEYLON J, Ma TM, Savjani R, Low DA, et al
     Quantifying Intrafraction Motion and the Impact of Gating for MRI-guided Stereotactic Radiotherapy for Prostate Cancer: Analysis of the MRI arm from the MIRAGE Phase III Randomized Trial.
     Int J Radiat Oncol Biol Phys. 2023 Dec 29:S0360-3016(23)08309.
     PubMed     Abstract available
     
     
     
112. ACHARD V, Zilli T, Lamanna G, Jorcano S, et al
     Urethra-sparing prostate cancer stereotactic body radiotherapy: sexual function and radiation dose to the penile bulb, the crura, and the internal pudendal arteries from a randomized phase 2 trial.
     Int J Radiat Oncol Biol Phys. 2023 Dec 29:S0360-3016(23)08307.
     PubMed     Abstract available
     
     
     
113. PATEL TA, Jain B, Vapiwala N, Chino F, et al
     Trends in Utilization and Medicare Spending on Short-Course Radiotherapy for Breast and Prostate Cancer: An Episode-Based Analysis from 2015-2019.
     Int J Radiat Oncol Biol Phys. 2023 Dec 8:S0360-3016(23)08173.
     PubMed     Abstract available
     
     
     
114. MENDEZ LC, Crook J, Martell K, Schaly B, et al
     Is ultra-hypofractionated whole pelvis radiotherapy (WPRT) as well tolerated as conventionally fractionated WPRT in prostate cancer patients? Early results from the HOPE Trial.
     Int J Radiat Oncol Biol Phys. 2023 Dec 8:S0360-3016(23)08189.
     PubMed     Abstract available
     
     
     
115. LUI AJ, Kallis K, Zhong AY, Hussain TS, et al
     ReIGNITE Radiation Therapy Boost: A Prospective, International Study of Radiation Oncologists' Accuracy in Contouring Prostate Tumors for Focal Radiation Therapy Boost on Conventional Magnetic Resonance Imaging Alone or With Assistance of Restriction
     Int J Radiat Oncol Biol Phys. 2023;117:1145-1152.
     PubMed     Abstract available
     
     
     
116. BRAND DH, Bruningk SC, Wilkins A, Naismith O, et al
     Gastrointestinal Toxicity Prediction Not Influenced by Rectal Contour or Dose-Volume Histogram Definition.
     Int J Radiat Oncol Biol Phys. 2023;117:1163-1173.
     PubMed     Abstract available
     
     
     
117. KYAW JYA, Rendall A, Gillespie EF, Roques T, et al
     Systematic Review and Meta-analysis of the Association Between Radiation Therapy Treatment Volume and Patient Outcomes.
     Int J Radiat Oncol Biol Phys. 2023;117:1063-1086.
     PubMed     Abstract available
     
     
     November 2023
118. GLICKSMAN RM, Loblaw A, Morton G, Vesprini D, et al
     Randomized trial of concomitant hypofractionated IMRT boost versus conventional fractionated IMRT boost for localized high-risk prostate cancer (pHART2-RCT).
     Int J Radiat Oncol Biol Phys. 2023 Nov 16:S0360-3016(23)08131.
     PubMed     Abstract available
     
     
     
119. ZILLI T, Jorcano S, Bral S, Symon Z, et al
     Every-Other-Day Versus Once-a-Week Urethra-Sparing Prostate Stereotactic Body Radiation Therapy: 5-Year Results of a Randomized Phase 2 Trial.
     Int J Radiat Oncol Biol Phys. 2023;117:791-798.
     PubMed     Abstract available
     
     
     
120. LIU G, Zhao L, Li X, Zhang S, et al
     A Novel Ultrahigh-Dose-Rate Proton Therapy Technology: Spot-Scanning Proton Arc Therapy + FLASH (SPLASH).
     Int J Radiat Oncol Biol Phys. 2023;117:730-737.
     PubMed     Abstract available
     
     
     
121. PETERSEN PM, Cook AD, Sydes MR, Clarke N, et al
     Salvage Radiation Therapy After Radical Prostatectomy: Analysis of Toxicity by Dose-Fractionation in the RADICALS-RT Trial.
     Int J Radiat Oncol Biol Phys. 2023;117:624-629.
     PubMed     Abstract available
     
     
     October 2023
122. FINK CA, Wegener D, Sauer LD, Lentz-Hommertgen A, et al
     Pelvic irradiation for node-positive prostate cancer after prostatectomy: Long-term results of the prospective PLATIN-4 and PLATIN-5 trials.
     Int J Radiat Oncol Biol Phys. 2023 Oct 18:S0360-3016(23)08012.
     PubMed     Abstract available
     
     
     
123. MOHAMAD O, Zamboglou C, Zilli T, Murthy V, et al
     Safety of ultra-hypofractionated pelvic nodal irradiation in the definitive management of prostate cancer: Systematic Review and Meta-analysis.
     Int J Radiat Oncol Biol Phys. 2023 Oct 18:S0360-3016(23)08006.
     PubMed     Abstract available
     
     
     
124. SHAHEEN H, Roach M 3rd, Salans MA, Mohamad O, et al
     Age 70 +/- 5 Years and Cancer Specific Outcomes after Treatment of Localized Prostate Cancer: A Systematic Review.
     Int J Radiat Oncol Biol Phys. 2023 Oct 1:S0360-3016(23)07930.
     PubMed     Abstract available
     
     
     September 2023
125. MENNE GURICOVA K, Groen V, Pos F, Monninkhof E, et al
     Risk Modeling for Individualization of the FLAME Focal Boost Approach in External Beam Radiation Therapy for Patients With Localized Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2023 Sep 18:S0360-3016(23)07732.
     PubMed     Abstract available
     
     
     
126. LI HZ, Qi X, Gao XS, Li XM, et al
     Dose-Intensified Postoperative Radiation Therapy for Prostate Cancer: Long-term Results from the PKUFH Randomized Phase III Trial.
     Int J Radiat Oncol Biol Phys. 2023 Sep 15:S0360-3016(23)07922.
     PubMed     Abstract available
     
     
     August 2023
127. YOROZU A, Namiki M, Saito S, Egawa S, et al
     Tri-modality Therapy with Iodine-125 Brachytherapy, External Beam Radiation Therapy, and Short- or Long-Term Androgen Deprivation Therapy for High-Risk Localized Prostate Cancer: Results of a Multicenter, Randomized Phase 3 Trial (TRIP/TRIGU0907).
     Int J Radiat Oncol Biol Phys. 2023 Aug 24:S0360-3016(23)07843.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum